# GeneDx Holdings Corp. (WGS)

Source: https://www.quantisnow.com/company/WGS
Generated: 2026-11-08T09:54:23.832Z

- Ticker: WGS
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Nursing Services
- IPO year: 2020
- SEC CIK: 0001818331

## Latest WGS news and filings

- 2026-11-06 17:35 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-genedx-holdings-corp-6778515)
- 2026-11-05 13:30 UTC [GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing](https://www.quantisnow.com/insight/genedx-and-mirum-pharmaceuticals-launch-sponsored-testing-programs-to-help-6775007)
- 2026-10-23 20:05 UTC [Earnings Date] [GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026](https://www.quantisnow.com/insight/genedx-to-report-third-quarter-2026-financial-results-on-monday-6756242)
- 2026-10-20 12:30 UTC [GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis](https://www.quantisnow.com/insight/genedx-expands-diagnostic-leadership-with-long-read-genome-sequencing-advancing-rare-6751631)
- 2026-10-19 20:05 UTC [GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026](https://www.quantisnow.com/insight/genedx-advances-clinical-adoption-of-genomic-medicine-with-27-abstracts-6750522)
- 2026-10-07 12:30 UTC [GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026](https://www.quantisnow.com/insight/genedx-presents-new-evidence-advancing-genomic-newborn-screening-at-icons-6739825)
- 2026-10-02 12:30 UTC [GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care](https://www.quantisnow.com/insight/genedx-introduces-easy-order-at-aap-2026-to-simplify-genomic-6733542)
- 2026-09-18 20:43 UTC [SEC Form 4] [CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $1,025,013 worth of shares (10,501 units at $97.61), increasing direct ownership by 8% to 115,476 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/chief-executive-officer-stueland-katherine-converted-options-into-18750-shares-6720721)
- 2026-09-18 20:39 UTC [SEC Form 4] [CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $363,892 worth of shares (3,728 units at $97.61), increasing direct ownership by 8% to 44,945 units (SEC Form 4) (tax withholding)](https://www.quantisnow.com/insight/chief-financial-officer-feeley-kevin-converted-options-into-7197-shares-6720714)
- 2026-09-18 20:37 UTC [SEC Form 4] [Director Fuchs Thomas converted options into 1,146 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-fuchs-thomas-converted-options-into-1146-shares-sec-form-6720711)
- 2026-09-11 20:13 UTC [SEC Form 4] [CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 6,547 shares and sold $310,932 worth of shares (3,692 units at $84.22), increasing direct ownership by 3% to 107,227 units (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/chief-executive-officer-stueland-katherine-converted-options-into-6547-shares-6713022)
- 2026-09-11 20:10 UTC [SEC Form 4] [CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 2,462 shares and sold $108,220 worth of shares (1,285 units at $84.22), increasing direct ownership by 3% to 41,476 units (SEC Form 4) to satisfy tax liability](https://www.quantisnow.com/insight/chief-financial-officer-feeley-kevin-converted-options-into-2462-shares-6713003)
- 2026-09-09 12:30 UTC [GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C](https://www.quantisnow.com/insight/genedx-and-beren-therapeutics-launch-npc-genomecomplete-to-improve-diagnosis-6709394)
- 2026-09-03 20:09 UTC [SEC Form 4] [CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 717 shares and sold $31,188 worth of shares (372 units at $83.84), increasing direct ownership by 0.86% to 40,299 units (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/chief-financial-officer-feeley-kevin-converted-options-into-717-shares-6705127)
- 2026-09-01 22:05 UTC [SEC Form 144] [SEC Form 144 filed by GeneDx Holdings Corp.](https://www.quantisnow.com/insight/sec-form-144-filed-by-genedx-holdings-corp-6701905)
- 2026-09-01 10:55 UTC [GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree](https://www.quantisnow.com/insight/genedx-ceo-katherine-stueland-recognized-as-a-2026-fierce-50-6700418)
- 2026-08-24 12:30 UTC [GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s](https://www.quantisnow.com/insight/genedx-announces-transformative-study-supporting-hospital-wide-adoption-of-rapid-genomic-6692204)
- 2026-08-11 23:29 UTC [SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-genedx-holdings-corp-6676671)
- 2026-08-11 12:30 UTC [GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy](https://www.quantisnow.com/insight/genedx-launches-new-online-offering-for-families-to-improve-accessibility-6675078)
- 2026-08-07 17:58 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by GeneDx Holdings Corp.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-genedx-holdings-corp-6671242)
- 2026-08-06 20:05 UTC [Conference Announcement] [GeneDx to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/genedx-to-participate-in-upcoming-investor-conferences-6668697)
- 2026-08-03 20:19 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by GeneDx Holdings Corp.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-genedx-holdings-corp-6659950)
- 2026-08-03 20:14 UTC [SEC Form 8-K] [GeneDx Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genedx-holdings-corp-filed-sec-form-8-k-results-of-operations-6659861)
- 2026-08-03 20:05 UTC [Earnings Date] [GeneDx Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/genedx-reports-second-quarter-2026-financial-results-6659605)
- 2026-07-21 20:08 UTC [SEC Form 25-NSE filed by GeneDx Holdings Corp.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-genedx-holdings-corp-6643800)
- 2026-07-16 20:05 UTC [Earnings Date] [GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026](https://www.quantisnow.com/insight/genedx-to-report-second-quarter-2026-financial-results-on-monday-6639634)
- 2026-07-01 20:10 UTC [SEC Form 4] [SEC Form 4 filed by President Gardner Mark A](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-gardner-mark-a-6622896)
- 2026-06-23 20:31 UTC [SEC Form 4] [Director Ryan Jason converted options into 3,576 shares, increasing direct ownership by 30% to 15,480 units (SEC Form 4)](https://www.quantisnow.com/insight/director-ryan-jason-converted-options-into-3576-shares-increasing-direct-6612781)
- 2026-06-23 20:30 UTC [SEC Form 4] [Director Ruch Joshua converted options into 3,576 shares, increasing direct ownership by 12% to 33,299 units (SEC Form 4)](https://www.quantisnow.com/insight/director-ruch-joshua-converted-options-into-3576-shares-increasing-direct-6612755)
- 2026-06-23 20:29 UTC [SEC Form 4] [Director Pfenniger Richard C Jr converted options into 3,576 shares, increasing direct ownership by 9% to 45,082 units (SEC Form 4)](https://www.quantisnow.com/insight/director-pfenniger-richard-c-jr-converted-options-into-3576-shares-6612709)
- 2026-06-23 20:28 UTC [SEC Form 4] [Director Meister Keith A. converted options into 3,576 shares, increasing direct ownership by 18% to 23,705 units (SEC Form 4)](https://www.quantisnow.com/insight/director-meister-keith-a-converted-options-into-3576-shares-increasing-6612698)
- 2026-06-23 20:27 UTC [SEC Form 4] [Director Leproust Emily M. converted options into 3,576 shares, increasing direct ownership by 17% to 24,852 units (SEC Form 4)](https://www.quantisnow.com/insight/director-leproust-emily-m-converted-options-into-3576-shares-increasing-6612686)
- 2026-06-23 20:26 UTC [SEC Form 4] [SEC Form 4 filed by Director Fuchs Thomas](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-fuchs-thomas-6612679)
- 2026-06-23 20:25 UTC [SEC Form 4] [Director Casdin Eli converted options into 3,576 shares, increasing direct ownership by 17% to 24,093 units (SEC Form 4)](https://www.quantisnow.com/insight/director-casdin-eli-converted-options-into-3576-shares-increasing-direct-6612673)
- 2026-06-23 12:35 UTC [SEC Form 8-K] [GeneDx Holdings Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/genedx-holdings-corp-filed-sec-form-8-k-submission-of-matters-6612021)
- 2026-06-18 20:11 UTC [SEC Form 4] [CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $226,597 worth of shares (3,729 units at $60.77), increasing direct ownership by 10% to 39,954 units (SEC Form 4) (tax withholding)](https://www.quantisnow.com/insight/chief-financial-officer-feeley-kevin-converted-options-into-7197-shares-6608682)
- 2026-06-18 20:09 UTC [SEC Form 4] [CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $638,104 worth of shares (10,501 units at $60.77), increasing direct ownership by 9% to 104,372 units (SEC Form 4) (withholding tax)](https://www.quantisnow.com/insight/chief-executive-officer-stueland-katherine-converted-options-into-18750-shares-6608626)
- 2026-06-16 20:10 UTC [SEC Form 3] [SEC Form 3 filed by new insider Gardner Mark A](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-gardner-mark-a-6604744)
- 2026-06-16 12:39 UTC [SEC Form 8-K] [GeneDx Holdings Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/genedx-holdings-corp-filed-sec-form-8-k-leadership-update-regulation-6604102)
- 2026-06-16 12:30 UTC [Leadership Update] [GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth](https://www.quantisnow.com/insight/genedx-names-mark-gardner-president-to-lead-its-next-phase-6604074)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/WGS
- Earnings history: https://www.quantisnow.com/earnings/WGS
- Dividend history: https://www.quantisnow.com/dividends/WGS
- Insider transactions: https://www.quantisnow.com/insiders/WGS
- Options chain: https://www.quantisnow.com/options/WGS
- SEC 8-K filings only: https://www.quantisnow.com/company/WGS/8-k
- RSS and alerts for WGS: https://www.quantisnow.com/docs/rss-feeds.md